Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast to p53, neither p73 nor p51 appears to be frequently mutated in human cancers on the basis of the limited studies reported to date.
|
10203277 |
1999 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We have investigated two hypotheses: (a) p73 is mutated in diverse types of human cancer, and (b) p73 is functionally redundant with p53 in carcinogenesis so that mutations would be exclusive in these two genes.
|
10362363 |
1999 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, a p53-related gene, termed p73, has been cloned and its gene product possesses a function similar to p53. p73 has been mapped at chromosome 1p36.3, a region frequently deleted in breast cancer, neuroblastoma and other malignancies.
|
10371354 |
1999 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, the distribution of genomic tp73 alleles in patients indicates that a role of this gene in the development of neuroblastoma cannot be completely ruled out.Int.J.Cancer (Pred.Oncol.)84:365-369, 1999.
|
10404087 |
1999 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p73 gene is located on 1p36.2-3, a region that is frequently deleted in human cancer.
|
10416592 |
1999 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among these, the cancer DNA of 12 revealed loss of heterozygosity (LOH) of p73.
|
10471526 |
1999 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition p73 and p63 are, in contrast to p53, rarely mutated in human cancer.
|
10618710 |
1999 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues.
|
10773878 |
2000 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, possibilities for new therapeutic applications with p73 for cancer cell control are discussed.
|
10972855 |
2000 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Wild type p73 overexpression and high-grade malignancy in breast cancer.
|
11510689 |
2001 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To explore the potential use of two p53 homologues, p73 and p51/p63, in cancer gene therapy, we introduced p53, p73 and p51/p63 into colorectal cancer cell lines via adenoviral vectors, and compared their effects on cell growth.
|
11571580 |
2001 |
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The p73 gene was methylated in 94% of cases, a frequency that is the highest known for any human malignancy.
|
11786399 |
2002 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the light of these new findings the contradictory role of p73 in malignancy will be discussed.
|
11859406 |
2002 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nonetheless, p63 and p73 genes seem strongly involved in malignancy acquisition and maintenance process because of: 1) their tissue identities, and 2) their close interplay activities within the p53 family members, and primarily through the negative regulatory role played by DeltaNp63/p73 isoforms for cell death control and differentiation.
|
12619104 |
2003 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In esophageal cancers, p73 immunoreactivity was observed in all intraepithelial lesions except one cancer, and was reduced with cancer invasion, to 78% and 64% at superficial invasion and deep invasion sites, respectively.
|
12841870 |
2003 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the functional impairment of p73 could be involved in the development of thyroid malignancies, defining p73 as a potential therapeutic target for thyroid cancer.
|
14522906 |
2003 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the last 2 years, it has become apparent that the p53-family members p53 and p73 play fundamentally different roles in human malignancies.
|
14618632 |
2004 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Functional regulation of p73 and p63: development and cancer.
|
14659698 |
2003 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The TP73 gene encodes a nuclear protein that has high homology with TP53.TP73 is rarely mutated in human cancer.
|
14732927 |
2004 |
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Accordingly, although TP73 aberrant methylation was more frequent in meningiomas with 1p deletion (P<0.05), no association with the grade of malignancy could be established.
|
14734228 |
2004 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two recently identified p53 homologues, p63 and p73, appear to function similarly to p53, that is, they both activate target gene expression and suppress cell growth when overexpressed; however, the p63 and p73 genes are rarely mutated in human cancer and do not adhere to Knudson's classical model of a tumor suppressor gene.
|
15095006 |
2004 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, despite a remarkable structural and partly functional similarity among p53, p63, and p73, mouse knockout studies revealed an unexpected functional diversity among them. p63 and p73 knockouts exhibit severe developmental abnormalities but no increased cancer susceptibility, whereas this picture is reversed for p53 knockouts.
|
15280445 |
2004 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results regarding a GC/AT polymorphism in the p73 gene in relation to cancer risk are inconsistent, and the significance of loss of heterozygosity (LOH) of the gene is unclear.
|
15485994 |
2005 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
From these findings we deduce that p73 isoform balance is disrupted in prostate cancer and BPH, suggesting that this disequilibrium could play an important role in both prostate hyperplasia and malignancy.
|
15492805 |
2004 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
p63, p73 and p53 compose a family of transcription factors involved in cell response to stress and development. p53 is the most frequently mutated gene in cancer (50%) and loss of p53 activity is considered to be ubiquitous to all cancers.
|
16601753 |
2006 |